Infinity shares battered over safety jitters

Shares of Infinity Pharmaceuticals ($INFI) took a beating on Monday, as investors reacted to some of the new safety data that the company reported on its PI3K delta/gamma inhibitor IPI-145 at ASCO. And even though shares regained some of that value on Tuesday, it's still far, far off the $50.09 52-week high recorded in early April. Infinity was reporting early-stage data on the drug, which has captured the attention of many in the biotech community. Story


Suggested Articles

It’s been a minute, but AstraZeneca has gotten the FDA’s all-clear to restart the U.S. study of its COVID-19 vaccine.

Combining KSQ's USP1 inhibitor with Merck and AstraZeneca's PARP inhibitor Lynparza was more effective in animal models than either drug on its own.

Solid Bio is teaming up with Ultragenyx on Duchenne muscular dystrophy in a deal worth $40 million upfront but could net it another $255 million.